Cutia Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Cutia Therapeutics has been growing earnings at an average annual rate of 73%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 341.4% per year.

Anahtar bilgiler

73.0%

Kazanç büyüme oranı

91.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi11.0%
Gelir büyüme oranı341.4%
Özkaynak getirisi-44.1%
Net Marj-263.7%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet?

Aug 30
Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet?

A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Jun 03
A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Apr 08
Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Gelir ve Gider Dağılımı

Cutia Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SEHK:2487 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24199-524420225
31 Mar 24168-1,244408220
31 Dec 23138-1,964395216
30 Sep 2391-1,954315202
30 Jun 2345-1,945235187
31 Mar 2328-1,250186184
31 Dec 2211-556136181
31 Dec 212-32071111

Kaliteli Kazançlar: 2487 is currently unprofitable.

Büyüyen Kar Marjı: 2487 is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: Insufficient data to determine if 2487's year-on-year earnings growth rate was positive over the past 5 years.

Büyüme Hızlandırma: Unable to compare 2487's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: 2487 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Özkaynak Getirisi

Yüksek ROE: 2487 has a negative Return on Equity (-44.12%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin